CGH
ALXN

Crossmark Global Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Crossmark Global Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,190
Closed -$2.79M – 1449
2021
Q2 		$2.79M Buy
15,190
+293
+2% +$50.3K 0.07% 292
2021
Q1 		$2.28M Sell
14,897
-930
-6% -$144K 0.06% 335
2020
Q4 		$2.47M Sell
15,827
-1,438
-8% -$185K 0.06% 325
2020
Q3 		$1.98M Sell
17,265
-104
-0.6% -$11.2K 0.06% 346
2020
Q2 		$1.95M Buy
17,369
+590
+4% +$62.6K 0.06% 344
2020
Q1 		$1.51M Buy
16,779
+913
+6% +$89.6K 0.05% 357
2019
Q4 		$1.72M Sell
15,866
-369
-2% -$39.5K 0.05% 414
2019
Q3 		$1.59M Sell
16,235
-628
-4% -$70.8K 0.05% 425
2019
Q2 		$2.21M Buy
16,863
+548
+3% +$70.6K 0.06% 355
2019
Q1 		$2.21M Sell
16,315
-85
-0.5% -$10.6K 0.06% 350
2018
Q4 		$1.6M Sell
16,400
-1,208
-7% -$143K 0.05% 414
2018
Q3 		$2.45M Sell
17,608
-1,061
-6% -$133K 0.06% 349
2018
Q2 		$2.32M Sell
18,669
-634
-3% -$74.1K 0.06% 349
2018
Q1 		$2.15M Sell
19,303
-2,014
-9% -$241K 0.06% 389
2017
Q4 		$2.55M Buy
21,317
+1,396
+7% +$170K 0.06% 363
2017
Q3 		$2.79M Buy
+19,921
New +$2.71M 0.07% 328
2016
Q3 		$2.79M Buy
+19,921
New +$2.56M 0.07% 328

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Crossmark Global Holdings's ALXN Position: Q3 2021 in Review

Crossmark Global Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 15,190 shares — an estimated $2.79M sold.

Crossmark Global Holdings first reported a position in ALXN in Q3 2016 and held it in 17 quarters. The position peaked at $2.79M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Crossmark Global Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Crossmark Global Holdings sold 15,190 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.79M.
  • Crossmark Global Holdings first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 17 quarters.
  • Crossmark Global Holdings's Alexion Pharmaceuticals position peaked at $2.79M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Crossmark Global Holdings's 13F filing for Q3 2021, filed 13 Oct 2021.